1. Home
  2. ATNM vs BAFN Comparison

ATNM vs BAFN Comparison

Compare ATNM & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.12

Market Cap

45.2M

Sector

Health Care

ML Signal

HOLD

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$6.95

Market Cap

40.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
BAFN
Founded
2000
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
45.2M
40.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ATNM
BAFN
Price
$1.12
$6.95
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
115.7K
18.7K
Earning Date
03-30-2026
01-29-2026
Dividend Yield
N/A
2.27%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,000.00
$39,595,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.11
N/A
52 Week Low
$1.03
$5.72
52 Week High
$2.41
$19.75

Technical Indicators

Market Signals
Indicator
ATNM
BAFN
Relative Strength Index (RSI) 33.16 50.95
Support Level $1.15 $6.28
Resistance Level $1.20 $8.44
Average True Range (ATR) 0.06 0.53
MACD -0.01 0.10
Stochastic Oscillator 6.24 35.14

Price Performance

Historical Comparison
ATNM
BAFN

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: